You may also like
https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com) – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for […]
NEW YORK, NEW YORK, UNITED STATES, September 9, 2020 /EINPresswire.com/ — Manhattan BioSolutions, a biotechnology company focused on the discovery of the […]
https://www.accesswire.com/709117/Manhattan-BioSolutions-Inc-Signs-Commercial-Evaluation-License-Agreements-with-the-National-Institutes-of-Health-NIH-for-Use-of-Monoclonal-Antibodies-in-Novel-Antibody-Drug-Conjugate-ADC-Oncology-Programs NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation […]